0.00Open0.02Pre Close0 Volume2.07K Open Interest108.00Strike Price0.00Turnover2339.61%IV8.29%PremiumDec 6, 2024Expiry Date0.00Intrinsic Value100Multiplier-5DDays to Expiry0.02Extrinsic Value100Contract SizeAmericanOptions Type0.0226Delta0.0225Gamma4987.50Leverage Ratio-164.9171Theta0.0000Rho112.76Eff Leverage0.0001Vega
Merck & Co Stock Discussion
On oct 10/24, open 2 x mrk contracts at 109.29c, strike at 105 and premium of 192 x 2 (35 dte). On nov 5/24, i closed 2 x contracts a...
Merck’s Investigational Zilovertamab Vedotin in Combination With R-CHP Demonstrates Complete Response Rate of 100% at 1.75 mg/kg Dose in Phase 2 Trial of Previously Untreated Patients With Diffuse Large B-Cell Lymphoma
Positive
100% complete response rate achieved at 1.75 mg/kg dose level
High overall response rate across all dosage groups (93.3-100%)
Strong 12-month duration of response at 93.5%
Successfully established recommended Phase 3 dose
Negative
58% of patients exp...
No comment yet